TL;DR
- Medical cannabis operators may now have access to the federal R&D tax credit. Adult-use cannabis remains subject to 280E.
- Cannabis is highly R&D-intensive. Cultivation trials, extraction improvements, formulations, testing, and process development may qualify.
- Existing records may be enough to support qualifying work. Purpose-built “R&D documentation” isn’t required.
- Important questions remain unresolved, particularly around DEA registration and prior-year claims.
R&D tax credits for cannabis companies have historically been out of reach, despite the surprising amount of research happening across the industry. Cannabis operators routinely test cultivars, refine nutrient programs, improve extraction yields, develop formulations, validate testing methods, and optimize production processes.
Historically, none of that mattered much for the federal R&D tax credit. Section 280E effectively put the credit off limits to cannabis businesses. Recent federal changes have opened a potential path for some medical cannabis operators – but who qualifies, what activities count, and how the new rules apply are still complicated.
Here’s what cannabis operators need to know.
What Changed for Cannabis Businesses
Before diving in, let’s first go over what Section 280E is and what it does.
Section 280E denies business deductions to anyone trafficking in a Schedule I or II controlled substance. It was established by Congress in 1982 after a court allowed an illegal drug dealer to deduct normal business costs like scales and briefcases.
For cannabis companies that meant no deductions for ordinary expenses such as for payroll, rent, or marketing, only for direct product costs. Effective federal rates above 70 percent were normal, and operators routinely paid tax in years they lost money.
On April 22, 2026, the Acting Attorney General signed an order effective April 28 moving two things to Schedule III:
- Cannabis in FDA-approved drug products
- Cannabis subject to a state medical marijuana license
Since 280E reaches only Schedules I and II, it no longer applies to those categories. Still in Schedule I: adult-use cannabis, unlicensed crops, and bulk cannabis outside the licensed medical channel. A broader rescheduling decision is pending.
The overlooked piece is the credit side.
Because 280E blocked credits as well as deductions, the federal R&D credit was effectively off limits to cannabis businesses – regardless of how much qualifying research they were actually doing. And in an industry built around cultivation science, formulation, extraction, testing and process improvement, that meant potentially significant tax value was being left on the table.
For medical cannabis operators, that may finally be changing. The question now is whether the work you’re already doing qualifies.
Could Your Cannabis Business Qualify?
Four questions can help determine whether there’s an opportunity.
01 | Are You Doing Qualifying R&D?
Cannabis R&D isn’t limited to work happening in a laboratory. If you’re testing alternatives to improve a product, process, formula, cultivation method, or technology, you may already be doing work that meets the federal test.
| CULTIVATION Strain and cultivar development Nutrient programs Environmental testing | EXTRACTION & PROCESSING Extraction methods Yield improvement Testing method validation |
| PRODUCT DEVELOPMENT Edibles, beverages, and topicals Formulation Shelf life and dosing | EQUIPMENT & TECHNOLOGY Equipment development Process improvements Software development |
But Not Every Improvement Is R&D
The federal test under Section 41 has four parts. The work must:
- Have a permitted purpose
Aim to create or improve a product, process, formula, or software. - Be technological in nature
Rely on science or engineering, including agricultural science and chemistry. - Involve technical uncertainty
Begin with genuine uncertainty about whether or how the desired result could be achieved. - Include a process of experimentation
Test alternatives, evaluate results, and iterate.
02 | Can You Document It?
Limited documentation does not automatically disqualify you.
Most cannabis operators haven’t been maintaining records specifically labeled “R&D.” Until now, there was little federal tax incentive to do so. But that doesn’t mean the evidence isn’t there.
- Batch records
- Trial logs
- Cultivation data
- Environmental data
- Formulation notes
- Testing results
- Production changes
- Payroll and supply records
- Contemporaneous business records never labeled as research are common and defensible.
- A claim assembled purely from after-the-fact recollection is where the IRS and courts push back hardest.
03 | Is Your Cannabis Eligible for the New Federal Treatment?
This is where cannabis R&D gets more complicated. Because Section 280E applies to Schedule I and II substances, the federal tax treatment depends first on what cannabis you handle – and potentially on your DEA registration status.Part A: What Do You Sell?
MEDICAL ONLY? Potential federal opportunity State-licensed medical cannabis is among the categories moved to Schedule III. MEDICAL + ADULT-USE? Split position Relief follows what you sell, not simply the license you hold. Expenses and research may need to be allocated between the two. ADULT-USE ONLY? No change Adult-use cannabis remains Schedule I and subject to 280E.Part B: Where do you stand on DEA registration?
Unsettled, and it matters most for growers. The same rule created a federal registration process for state licensees. For cultivators it includes an unusual step: DEA buys your crop at a nominal price and sells it back at the same price plus a fee, with the crop held somewhere DEA can access until the transaction closes. Fees run roughly $3,700 a year for manufacturers, $1,850 for distributors, and $888 for three years for dispensers. The issue is that the rule points in two directions:- The rule ties Schedule III treatment to state-licensed cannabis meeting DEA purchase-and-sale requirements, which apply to registered businesses.
- Elsewhere the same rule says state licensees are simply no longer subject to 280E, with no mention of registration.
- Those statements have not been reconciled, and Treasury has not weighed in.
04 | Can You Use the Credit?
Qualifying for the R&D credit and being able to use it immediately are two different things. The federal R&D credit is generally nonrefundable, meaning it cannot reduce a given year’s tax below zero. How the value reaches your business depends on your tax position.What About Past Years?
Normally, an R&D study can look back across open tax years. If a business paid tax but didn’t claim an available credit, an amended return can potentially turn that credit into a refund.
Cannabis businesses have an additional complication. Because 280E prevented these businesses from claiming the federal credit in prior years, whether the new treatment can support claims for earlier periods remains an unresolved question pending federal guidance.
State Treatment Is a Separate Analysis
Everything above concerns the federal R&D credit and federal 280E treatment. State treatment runs on its own track.
Many states decoupled from 280E years ago. In those states, licensed operators have already been able to deduct ordinary expenses and claim available state-level credits, including state R&D credits where offered, regardless of federal treatment. California and Michigan are common examples and not the only ones.
- Decoupled state: none of the federal uncertainty above changes your state position. The April rescheduling adds a federal layer that was previously unavailable.
- Conforming state, or no state R&D credit: the federal change is the whole story for you.
State conformity varies considerably, and the analysis has to run federal and state together.
What to Do Now
Much of this is still taking shape. Treasury guidance has not issued, the DEA registration question is unresolved, retroactivity is open, and the broader rescheduling decision is pending. Some of these will be settled by guidance and some by the courts over the next few years. Anyone offering certainty right now is overstating what exists.
That is not a reason to wait, because documentation is the one thing entirely within your control and the one thing you cannot create retroactively. Starting now costs little and preserves your options however the open questions resolve.
Beyond that, get an informed read on your specific situation. Your position depends on your licenses, what you sell, your state, your registration status, and what you are actually developing. A conversation with your CPA or an experienced specialty tax firm will tell you more than any article can, including whether this is worth pursuing now or better revisited once guidance lands.
FAQs
Medical licensees can begin evaluating it, which was not previously possible, because federal 280E blocked credits as well as deductions. You still need qualifying research, supporting documentation, and federal tax liability to offset. Treasury guidance is pending. Operators in decoupled states may already have been claiming state-level credits.
Not automatically. Drug schedules classify substances, not companies, so your license does not put your business in Schedule III. It affects the classification of the cannabis you handle, and 280E then depends on what you actually sell. There is also an unresolved question about whether DEA registration factors in.
The April rule created an expedited registration process for state licensees, and handling a Schedule III substance generally requires registration. Whether it is specifically required for the 280E relief is unsettled. The initial 60-day window closed in late June 2026.
Nothing has changed. Adult-use cannabis remains Schedule I and subject to 280E. A broader rescheduling decision is pending.
Strain and cultivar development, nutrient and environmental testing, extraction method development, product formulation, testing method validation, and equipment or software development commonly qualify. The key is genuine technical uncertainty worked through systematically, rather than repeating a known process.
The legal question is unresolved and awaiting Treasury guidance. On the practical side, limited documentation is not automatically disqualifying. Most operators never labeled their work as research, but the underlying business records often still exist and a specialist can map them to the technical requirements. What does not work is a claim built solely on recollection with no supporting trail.
The Bottom Line
Royse Partners runs R&D credit studies with engineers who understand the technical work itself, the cultivation science, extraction chemistry, formulation, and process engineering. In an industry this technical and a year this unsettled, that is what separates what genuinely qualifies from what does not. If you want to know where your operation stands, we are glad to talk it through.